FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360747507> ?p ?o ?g. }

• W4360747507 abstract "You have accessJournal of UrologyCME1 Apr 2023MP67-16 SURGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT VACCINE THERAPY (PROSTVAC) PRIOR TO RADICAL PROSTATECTOMY: A PHASE II EXPERIENCE Zoe Blake, Daniel Nemirovsky, Alexander Kenigsberg, Neil Mendhiratta, Jacob Enders, Michael Rothberg, Daniel Nethala, Baris Turkbey, Bradford Wood, Sandeep Gurram, Howard Parnes, James Gulley, and Peter Pinto Zoe BlakeZoe Blake More articles by this author , Daniel NemirovskyDaniel Nemirovsky More articles by this author , Alexander KenigsbergAlexander Kenigsberg More articles by this author , Neil MendhirattaNeil Mendhiratta More articles by this author , Jacob EndersJacob Enders More articles by this author , Michael RothbergMichael Rothberg More articles by this author , Daniel NethalaDaniel Nethala More articles by this author , Baris TurkbeyBaris Turkbey More articles by this author , Bradford WoodBradford Wood More articles by this author , Sandeep GurramSandeep Gurram More articles by this author , Howard ParnesHoward Parnes More articles by this author , James GulleyJames Gulley More articles by this author , and Peter PintoPeter Pinto More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003330.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: PROSTVAC is a therapeutic cancer vaccine designed to activate T cells specific against prostate-specific antigen (PSA). Previous trials have shown PROSTVAC to be safe and capable of modulating immune responses in patients with localized prostate cancer (PCa). We aim to examine the surgical safety and feasibility outcomes of patients in a phase II trial (NCT02153918) investigating the neoadjuvant use of this vaccine therapy in patients with localized PCa. METHODS: An open-label, phase II study of neoadjuvant PROSTVAC vaccine enrolled patients with histopathologically confirmed localized PCa who were surgical candidates for radical prostatectomy (RP). Patients received recombinant vaccinia (rV)-PSA(L155)-TRICOM (PROSTVAC) as a priming vaccination, followed by monthly boosts on weeks 5, 9 and 13 with recombinant fowlpox (rF)-PROSTVAC. The boosting schedule was amended mid-trial to weeks 3, 5 and 9 to allow for earlier surgeries. After completing the vaccination series, patients underwent RP at week 10. Final follow-up safety evaluation was performed 12–15 months postoperatively. RESULTS: Between 2014-2016, 26 of 27 enrolled patients went on to receive RP. On pre-RP biopsy, 12/26 (46.2%) of patients had Gleason grade group (GG) 1-2, and 14/26 (53.8%) of patients had GG 3-5 (Table 1). Two patients (7.7%) were upgraded, and five (19.2%) downgraded on final pathology. Rates of adverse features at RP are shown in Table 2. The most common adverse event (AE) was a self-limited injection-site reaction (28 events in 18 patients), and no serious AEs or toxicities>grade 2 were attributed to PROSTVAC. However, two grade 3 serious AEs occurred: an infected lymphocele and a thromboembolic event, both attributed to surgery. CONCLUSIONS: PROSTVAC was well tolerated and demonstrated the feasibility of neoadjuvant vaccination strategies for localized PCa. Further studies will be needed to elucidate the effectiveness of this vaccine therapy on short and long-term oncologic outcomes. Source of Funding: NIH intramural research program © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e949 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Zoe Blake More articles by this author Daniel Nemirovsky More articles by this author Alexander Kenigsberg More articles by this author Neil Mendhiratta More articles by this author Jacob Enders More articles by this author Michael Rothberg More articles by this author Daniel Nethala More articles by this author Baris Turkbey More articles by this author Bradford Wood More articles by this author Sandeep Gurram More articles by this author Howard Parnes More articles by this author James Gulley More articles by this author Peter Pinto More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360747507 created "2023-03-24" @default.
• W4360747507 creator A5007153736 @default.
• W4360747507 creator A5009700206 @default.
• W4360747507 creator A5009772670 @default.
• W4360747507 creator A5013500099 @default.
• W4360747507 creator A5022455023 @default.
• W4360747507 creator A5026470145 @default.
• W4360747507 creator A5038850729 @default.
• W4360747507 creator A5043129088 @default.
• W4360747507 creator A5055870934 @default.
• W4360747507 creator A5065359790 @default.
• W4360747507 creator A5068400172 @default.
• W4360747507 creator A5070669850 @default.
• W4360747507 creator A5077655013 @default.
• W4360747507 date "2023-04-01" @default.
• W4360747507 modified "2023-10-16" @default.
• W4360747507 title "MP67-16 SURGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT VACCINE THERAPY (PROSTVAC) PRIOR TO RADICAL PROSTATECTOMY: A PHASE II EXPERIENCE" @default.
• W4360747507 doi "https://doi.org/10.1097/ju.0000000000003330.16" @default.
• W4360747507 hasPublicationYear "2023" @default.
• W4360747507 type Work @default.
• W4360747507 citedByCount "0" @default.
• W4360747507 crossrefType "journal-article" @default.
• W4360747507 hasAuthorship W4360747507A5007153736 @default.
• W4360747507 hasAuthorship W4360747507A5009700206 @default.
• W4360747507 hasAuthorship W4360747507A5009772670 @default.
• W4360747507 hasAuthorship W4360747507A5013500099 @default.
• W4360747507 hasAuthorship W4360747507A5022455023 @default.
• W4360747507 hasAuthorship W4360747507A5026470145 @default.
• W4360747507 hasAuthorship W4360747507A5038850729 @default.
• W4360747507 hasAuthorship W4360747507A5043129088 @default.
• W4360747507 hasAuthorship W4360747507A5055870934 @default.
• W4360747507 hasAuthorship W4360747507A5065359790 @default.
• W4360747507 hasAuthorship W4360747507A5068400172 @default.
• W4360747507 hasAuthorship W4360747507A5070669850 @default.
• W4360747507 hasAuthorship W4360747507A5077655013 @default.
• W4360747507 hasConcept C121608353 @default.
• W4360747507 hasConcept C126322002 @default.
• W4360747507 hasConcept C2778292576 @default.
• W4360747507 hasConcept C2779466945 @default.
• W4360747507 hasConcept C2780192828 @default.
• W4360747507 hasConcept C2781406297 @default.
• W4360747507 hasConcept C530470458 @default.
• W4360747507 hasConcept C61434518 @default.
• W4360747507 hasConcept C71924100 @default.
• W4360747507 hasConceptScore W4360747507C121608353 @default.
• W4360747507 hasConceptScore W4360747507C126322002 @default.
• W4360747507 hasConceptScore W4360747507C2778292576 @default.
• W4360747507 hasConceptScore W4360747507C2779466945 @default.
• W4360747507 hasConceptScore W4360747507C2780192828 @default.
• W4360747507 hasConceptScore W4360747507C2781406297 @default.
• W4360747507 hasConceptScore W4360747507C530470458 @default.
• W4360747507 hasConceptScore W4360747507C61434518 @default.
• W4360747507 hasConceptScore W4360747507C71924100 @default.
• W4360747507 hasIssue "Supplement 4" @default.
• W4360747507 hasLocation W43607475071 @default.
• W4360747507 hasOpenAccess W4360747507 @default.
• W4360747507 hasPrimaryLocation W43607475071 @default.
• W4360747507 hasRelatedWork W189616576 @default.
• W4360747507 hasRelatedWork W1995011828 @default.
• W4360747507 hasRelatedWork W2007050830 @default.
• W4360747507 hasRelatedWork W2024830492 @default.
• W4360747507 hasRelatedWork W2107251918 @default.
• W4360747507 hasRelatedWork W2111238914 @default.
• W4360747507 hasRelatedWork W2114399000 @default.
• W4360747507 hasRelatedWork W2395453437 @default.
• W4360747507 hasRelatedWork W2786928931 @default.
• W4360747507 hasRelatedWork W2981967612 @default.
• W4360747507 hasVolume "209" @default.
• W4360747507 isParatext "false" @default.
• W4360747507 isRetracted "false" @default.
• W4360747507 workType "article" @default.